Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05676099 · ClinicalTrials.gov registry record
TSC Biosample Repository and Natural History Database
A clinical trial of Lymphangioleiomyomatosis and Tuberous Sclerosis, sponsored by National Tuberous Sclerosis Association.
- Recruiting
- Registry status
- 5,000
- Enrollment target
- 20
- Study locations
NCT05676099 is a study of Lymphangioleiomyomatosis and Tuberous Sclerosis that is actively recruiting participants, run by National Tuberous Sclerosis Association. The registered enrollment target is 5,000 participants, above the 330-participant average among 10 other Lymphangioleiomyomatosis trials with a reported enrollment target (1415% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT05676099, a study of Lymphangioleiomyomatosis and Tuberous Sclerosis, is actively recruiting participants, sponsored by National Tuberous Sclerosis Association.
- RECRUITING
- Registry status
- 5,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The TSC Biosample Repository collects and stores samples of blood, DNA, and tissues that scientists can request to use in their research. The samples we collect are all linked to clinical data in the TSC Natural History Database. The TSC Natural History Database captures clinical data to document the impact of the disease on a person's health over his or her lifetime. This data may be collected retrospectively or prospectively.
Conditions Studied
Interventions
- PROCEDURE Phlebotomy
- PROCEDURE Buccal (cheek) swab
- GENETIC Genetic Testing
- OTHER Tissue donation after routine clinical procedure
Study Locations (20)
California
- Loma Linda University Children's Hospital - Loma Linda
- University of California Los Angeles - Los Angeles
- Jack & Julia Center for TSC, Oakland Children's Hospital and Research Center - Oakland
Massachusetts
- Boston Children's Hospital - Boston
- Massachusetts General Hospital - Boston
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Cleveland Clinic Foundation - Cleveland
Texas
- Scottish Rite Hospital for Children - Dallas
- Texas Childrens Hospital Baylor College of Medicine - Houston
Alabama
- University of Alabama Birmingham - Birmingham
Colorado
- The Children's Hospital - Denver
Florida
- Nicklaus Children's Hospital - Miami
Illinois
- Chicago Comer Children's Hospital Neurogenetic Clinic, University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2016-01 |
| Est. Completion | 2050-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05676099
The ClinicalTrials.gov registry entry for NCT05676099 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 330-participant average among 10 other Lymphangioleiomyomatosis trials with a reported enrollment target (1415% higher). The listed sponsor is National Tuberous Sclerosis Association, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphangioleiomyomatosis appearing as the primary indexed condition, and to 4 interventions - of which Phlebotomy is the first listed.
NCT05676099 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Massachusetts, Ohio.
Frequently Asked Questions
What is clinical trial NCT05676099 about?
NCT05676099 is a clinical study titled "TSC Biosample Repository and Natural History Database". The TSC Biosample Repository collects and stores samples of blood, DNA, and tissues that scientists can request to use in their research. The samples we collect are all linked to clinical data in the TSC Natural History Database. The TSC Natural History Database captures clinical data to document th...
What is the current status of trial NCT05676099?
This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2016-01. Estimated completion is 2050-12.
What conditions does trial NCT05676099 study?
This clinical trial studies the following conditions: Lymphangioleiomyomatosis, Tuberous Sclerosis.
What interventions are being tested in trial NCT05676099?
The interventions under investigation include: Phlebotomy (PROCEDURE), Buccal (cheek) swab (PROCEDURE), Genetic Testing (GENETIC), Tissue donation after routine clinical procedure (OTHER).
Who is sponsoring clinical trial NCT05676099?
This trial is sponsored by National Tuberous Sclerosis Association, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05676099 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphangioleiomyomatosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
RECRUITING · Phase 1
-
Safety and Durability of Sirolimus for Treatment of LAM
RECRUITING
-
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
RECRUITING
-
Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)
RECRUITING · Phase 1
-
Study of the Disease Process of Lymphangioleiomyomatosis
RECRUITING
-
Feasibility of [11C]Acetate-PET in LAM and TSC
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.